415P - Modification CT/MRI demonstration after radiation therapy for pituitary somatotropinomas

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Endocrine Tumours
Staging Procedures (clinical staging)
Surgical Oncology
Presenter Saodat Issaeva
Citation Annals of Oncology (2016) 27 (suppl_9): ix130-ix131. 10.1093/annonc/mdw590
Authors S.S. Issaeva, Z.Y. Khalimova, A.O. Khalikova, S.M. Safarova
  • Republican Specialized Scientific And Practical Medical Center Of Endocrinology Uzbekistan, Republican Specialized Scientific and Practical Medical Center of Endocrinology Uzbekistan, 100125 - Tashkent/UZ



The purpose of research - to study the dynamics of imaging performance after radiotherapy at pituitary somatotropinomas


The study included 30 patients who received radiation therapy at a dose of 45 Gr to 25 fraction of a day. Of them 21 (70%) females, 9 (30%) men. The age of patients ranged from 36 to 71 years. Duration of illness was an average of 15 years. The periods of observation after radiotherapy was an average of 10 years.


Before and after radiotherapy patients underwent CT/MRI of brain research covering the pituitary gland, as well as the levels of pituitary hormones studied: GH, IGF-1, PRL, TSH, LH, FSH, Fr.T4, cortisol, testosterone.


Before RT in 20 (67%) patients were macroadenoma, in 10(33%) of patients with giant pituitary adenoma. Of them 11(37%) patients received primary radiation therapy, 10(33%) patients after the surgery and 9(30%) after drug therapy.


After radiotherapy conducted clinical and neuroimaging studies (in terms of 3-5 years) found in 15 (50%) patients had a decrease of somatotropinomas, in 6 (20%) the dynamics of change was not, in 8 (27%) the continuation of the growth of education.


Analyzing morbidity after held RT, it should be noted that 28 (93%) hypothyroidism, 6 (20%) hypocorticizm, 11 (37%) of hypogonadism, 7 (23%) of hyperprolactinemia, 13 (43%) of hypopituitarism and 30 (100%), post-radiation encephalopathy.


Thus, LT is the method of choice in the treatment of pituitary growth hormone and 70% and improves the stabilization process.

Clinical trial indentification

Legal entity responsible for the study

Khalimova Zamira Yusupovna




All authors have declared no conflicts of interest.